Predictive Value of AKT/MTOR Pathway Immunohistochemical (IHC) Biomarkers for Response to Preoperative Trastuzumab (T) vs Trastuzumab + Everolimus (T + E) in Patients (PTS) with Early Breast Cancer (BC): Unicancer Radher Trial Results
Titel:
Predictive Value of AKT/MTOR Pathway Immunohistochemical (IHC) Biomarkers for Response to Preoperative Trastuzumab (T) vs Trastuzumab + Everolimus (T + E) in Patients (PTS) with Early Breast Cancer (BC): Unicancer Radher Trial Results
Auteur:
Campone, M. Bachelot, T. Paoletti, X. Merlin, J. Delaloge, S. Loussouarn, D. Bonneterre, J. Jimenez, M. Rios, M. Treilleux, I.